Current research status and application prospects of mesenchymal stem cell-derived exosomes in islet transplantation
10.12464/j.issn.1674-7445.2024194
- VernacularTitle:间充质干细胞来源的外泌体在胰岛移植中的作用研究现状及应用前景
- Author:
Rui LI
1
;
Dianxiang WANG
1
;
Zhaowei LIANG
1
;
Bing HAN
1
;
Hao LIAN
1
Author Information
1. Second Department of Oncology Surgery, Chifeng Cancer Hospital, Chifeng 024000, China.
- Publication Type:ReviewArticle
- Keywords:
Type 1 diabetes mellitus;
Islet transplantation;
Mesenchymal stem cell;
Exosome;
Inflammatory response;
Vascular reconstruction;
Islet regeneration;
Drug delivery
- From:
Organ Transplantation
2025;16(1):163-168
- CountryChina
- Language:Chinese
-
Abstract:
Type 1 diabetes mellitus is a chronic autoimmune disease caused by the destruction of pancreatic islet β cells. Pancreatic islet transplantation provides a treatment method for patients with type 1 diabetes mellitus to restore endogenous insulin secretion. However, some problems limit the widespread application of islet transplantation, such as the shortage of donors and post-transplantation rejection damage. Mesenchymal stem cell-derived exosome (MSC-Exo) has become a potential tool for islet transplantation therapy due to their immunomodulatory and tissue repair capabilities. MSC-Exo shows great promise for application, because of low immunogenicity, easily being stored and transported, and the potential as drug delivery vehicles. However, challenges such as preparation, purification, standardization and safety verification need to be overcome before converting MSC-Exo into clinical practice. Therefore, this article reviews the application and potential advantages of MSC-Exo in islet transplantation, aiming to providing more effective and safer treatment options for patients with type 1 diabetes mellitus.
